Literature DB >> 2365469

Antistaphylococcal antibodies in cystic fibrosis.

B Strandvik1, A Hollsing, R Möllby, M Granström.   

Abstract

Chronic colonization with Staphylococcus aureus is found in 40-50% of the sputum producing patients with cystic fibrosis treated at Stockholm's Cystic Fibrosis Center, Huddinge University Hospital. 30-40% of these patients had increased ELISA IgG antibody titres against teichoic acid and against alpha-toxin. About half of the number of patients showed increased antibody titres to either antigen during infection. Increased antibody titres against staphylococcal antigens were only found in less than or equal to 10% of patients not chronically colonized with S. aureus (no different from the normal population). The serum titres of antistaphylococcal antibodies were significantly higher in the chronically colonized patients (p less than 0.001). Patients who were also chronically harbouring Pseudomonas aeruginosa had the highest titres of both antibodies. The titres increased with clinical signs of infection and were normalized by antimicrobial chemotherapy. To conclude, the use of ELISA IgG antibodies may prove suitable for routine evaluation of the need for, and control of the efficacy of antistaphylococcal chemotherapy in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365469     DOI: 10.1007/bf01642107

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

Authors:  L L Kulczycki; T M Murphy; J A Bellanti
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

2.  Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysins and teichoic acid.

Authors:  M Granström; I Julander; R Möllby
Journal:  Scand J Infect Dis Suppl       Date:  1983

3.  Enzyme-linked immunosorbent assay for antibodies against teichoic acid in patients with staphylococcal infections.

Authors:  M Granström; I G Julander; S A Hedström; R Möllby
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

4.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  Distinguishing complicated from uncomplicated bacteremia caused by Staphylococcus aureus: the value of "new" and "old" serological tests.

Authors:  H A Verbrugh; R Peters; W H Goessens; M F Michel
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

6.  The in-vitro activity of ceftazidime against clinically important pathogens.

Authors:  H Knothe; G A Dette
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

7.  The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections.

Authors:  I G Julander; M Granström; S A Hedström; R Möllby
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

8.  Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.

Authors:  M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1982-09

9.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

10.  Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis.

Authors:  M Granström; A Ericsson; B Strandvik; B Wretlind; O R Pavlovskis; R Berka; M L Vasil
Journal:  Acta Paediatr Scand       Date:  1984-11
View more
  3 in total

1.  Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients.

Authors:  A Bauernfeind; B Przyklenk; C Matthias; R Jungwirth; R M Bertele; K Harms
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

2.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

3.  Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population.

Authors:  F Karpati; A S Malmborg; H Alfredsson; L Hjelte; B Strandvik
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.